Cargando…

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer

Detalles Bibliográficos
Autores principales:	Al-Rajabi, Taiseer, Naidoo, Jarushka, Zhang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517860/ https://www.ncbi.nlm.nih.gov/pubmed/37746275 http://dx.doi.org/10.3389/fonc.2023.1277542

Ejemplares similares

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs
por: Balaji, Aanika, et al.
Publicado: (2020)

Editorial: Impact of immunotherapy in lung cancer
por: Ferreira, Marion, et al.
Publicado: (2022)

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
por: Bredin, Philip, et al.
Publicado: (2022)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
por: Yang, Ruoning, et al.
Publicado: (2022)

Editorial: Personalized immunotherapy for cancer
por: Pasetto, Anna, et al.
Publicado: (2023)

Immunotherapy through the Lens of Non-Small Cell Lung Cancer
por: Stanley, Robyn, et al.
Publicado: (2023)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022)

Editorial: Engineered Targeted Cancer Immunotherapies
por: Fantini, Massimo, et al.
Publicado: (2022)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
por: Tolba, Mai F., et al.
Publicado: (2021)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
por: Wang, Yusha, et al.
Publicado: (2023)

Editorial: Immunology and Immunotherapy of Head and Neck Cancer
por: Gavrielatou, Niki, et al.
Publicado: (2021)

Editorial: Advancements in immunology and immunotherapy for breast cancer
por: Sugie, Tomoharu, et al.
Publicado: (2022)

Editorial: Emerging engineering approaches in cancer immunotherapy
por: Xu, Jialu, et al.
Publicado: (2022)

Editorial: Tumor immune microenvironment topographies for prediction and evaluation: unlock the mystery of the therapeutic effects and adverse events of tumor immunotherapy
por: Yin, Xiaoran, et al.
Publicado: (2023)

Editorial: The role of immunotherapy in melanomas
por: Fateeva, Anna, et al.
Publicado: (2023)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy
por: Yang, Jieying, et al.
Publicado: (2023)

Editorial: Biomarkers and immunotherapy of hepatic-biliary-pancreatic cancers
por: Qian, Yawei, et al.
Publicado: (2023)

Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy
por: Abu Eid, Rasha
Publicado: (2019)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Editorial: Optimizing surgical procedures in renal cancers to improve patient outcomes
por: Patel, Hiten D., et al.
Publicado: (2022)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Editorial: Adverse and Toxic Effects of Childhood Cancer Treatments
por: Ruggiero, Antonio, et al.
Publicado: (2021)

Editorial: Tailoring immunotherapy in gastrointestinal cancer: the role of circulating factors
por: Ugel, Stefano, et al.
Publicado: (2023)

Editorial: Genomics and Epigenomics of Cancer Immunotherapy: Challenges and Clinical Implications
por: Abedalthagafi, Malak
Publicado: (2021)

Editorial: The Evolving Role of Immunotherapy in Non-Melanoma Skin Cancers
por: Guida, Michele, et al.
Publicado: (2022)

Editorial: Novel immunotherapies to treat gastrointestinal solid tumor cancers
por: Sureban, Sripathi M., et al.
Publicado: (2022)

Editorial: Imaging assessment of response to immunotherapy
por: Occhipinti, Mariaelena, et al.
Publicado: (2023)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

Editorial: The Biological Landscape of Immunotherapy in AML
por: Isidori, Alessandro, et al.
Publicado: (2021)

Editorial: Epigenetic Regulation and Tumor Immunotherapy
por: Sun, Hongyin, et al.
Publicado: (2022)

Editorial: Immunotherapy in renal cell carcinoma
por: Gruenwald, Viktor, et al.
Publicado: (2022)

The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?
por: Page, David B, et al.
Publicado: (2015)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

The Resistance Mechanisms of Lung Cancer Immunotherapy
por: Wang, Fen, et al.
Publicado: (2020)

Viral Infection and Lung Cancer Immunotherapy
por: Kalinka, Ewa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8kshill8f80n9878lroh0v6vdj